Review





Similar Products

filamin a antibody / flna  (NSJ Bioreagents)
99
NSJ Bioreagents filamin a antibody / flna
Filamin A Antibody / Flna, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/filamin a antibody / flna/product/NSJ Bioreagents
Average 99 stars, based on 1 article reviews
filamin a antibody / flna - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
anti flna  (Proteintech)
93
Proteintech anti flna
Anti Flna, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti flna/product/Proteintech
Average 93 stars, based on 1 article reviews
anti flna - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
primary antibodies  (Proteintech)
93
Proteintech primary antibodies
Primary Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies/product/Proteintech
Average 93 stars, based on 1 article reviews
primary antibodies - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
cells  (Proteintech)
93
Proteintech cells
Cells, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cells/product/Proteintech
Average 93 stars, based on 1 article reviews
cells - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
buffer flna  (Proteintech)
93
Proteintech buffer flna
Buffer Flna, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/buffer flna/product/Proteintech
Average 93 stars, based on 1 article reviews
buffer flna - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
flna  (Proteintech)
93
Proteintech flna
Validation of 1-day and 14-day treatment transcriptomics data using IHC. A, Left, CCL2 transcript expression in OVCAR3-, FT240-, and PBS-treated secretory cells after 1 day. Right, IHC staining for upregulated CCL2 in FTE from three individual patients. B, Left, <t>FLNA</t> transcript expression in OVCAR3-, FT240-, and PBS-treated secretory cells after 1 day. Right, IHC staining for downregulated FLNA in FTE from three individual patients. C, <t>Left,</t> <t>VCAM1</t> transcript expression in OVCAR3-, FT240-, and PBS-treated secretory cells after 1 day. Right, IHC staining for upregulated VCAM1 in FTE from three individual patients. D, Left, TPI1 transcript expression in OVCAR3-, FT240-, PBS-treated secretory cells after 1 day. Right, IHC staining for downregulated protein TPI1 in FTE from three individual patients. E, Left, TXNIP transcript expression in OVCAR3-, FT240-, and PBS-treated secretory cells after 14 days. Right, IHC staining for downregulated TXNIP in FTE from three individual patients. F, Left, VCAM1 transcript expression in OVCAR3-, FT240-, and PBS-treated ciliated cells after 14 days. Right, IHC staining for upregulated VCAM1 in FTE from three individual patients. In all boxplots, each point represents normalized transcript abundance measured in a single segment. Scale bar, 20 μm; arrows indicate epithelium.
Flna, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/flna/product/Proteintech
Average 93 stars, based on 1 article reviews
flna - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


Validation of 1-day and 14-day treatment transcriptomics data using IHC. A, Left, CCL2 transcript expression in OVCAR3-, FT240-, and PBS-treated secretory cells after 1 day. Right, IHC staining for upregulated CCL2 in FTE from three individual patients. B, Left, FLNA transcript expression in OVCAR3-, FT240-, and PBS-treated secretory cells after 1 day. Right, IHC staining for downregulated FLNA in FTE from three individual patients. C, Left, VCAM1 transcript expression in OVCAR3-, FT240-, and PBS-treated secretory cells after 1 day. Right, IHC staining for upregulated VCAM1 in FTE from three individual patients. D, Left, TPI1 transcript expression in OVCAR3-, FT240-, PBS-treated secretory cells after 1 day. Right, IHC staining for downregulated protein TPI1 in FTE from three individual patients. E, Left, TXNIP transcript expression in OVCAR3-, FT240-, and PBS-treated secretory cells after 14 days. Right, IHC staining for downregulated TXNIP in FTE from three individual patients. F, Left, VCAM1 transcript expression in OVCAR3-, FT240-, and PBS-treated ciliated cells after 14 days. Right, IHC staining for upregulated VCAM1 in FTE from three individual patients. In all boxplots, each point represents normalized transcript abundance measured in a single segment. Scale bar, 20 μm; arrows indicate epithelium.

Journal: Cancer Research Communications

Article Title: Defining the Ovarian Cancer Precancerous Landscape through Modeling Fallopian Tube Epithelium Reprogramming Driven by Extracellular Vesicles

doi: 10.1158/2767-9764.CRC-25-0064

Figure Lengend Snippet: Validation of 1-day and 14-day treatment transcriptomics data using IHC. A, Left, CCL2 transcript expression in OVCAR3-, FT240-, and PBS-treated secretory cells after 1 day. Right, IHC staining for upregulated CCL2 in FTE from three individual patients. B, Left, FLNA transcript expression in OVCAR3-, FT240-, and PBS-treated secretory cells after 1 day. Right, IHC staining for downregulated FLNA in FTE from three individual patients. C, Left, VCAM1 transcript expression in OVCAR3-, FT240-, and PBS-treated secretory cells after 1 day. Right, IHC staining for upregulated VCAM1 in FTE from three individual patients. D, Left, TPI1 transcript expression in OVCAR3-, FT240-, PBS-treated secretory cells after 1 day. Right, IHC staining for downregulated protein TPI1 in FTE from three individual patients. E, Left, TXNIP transcript expression in OVCAR3-, FT240-, and PBS-treated secretory cells after 14 days. Right, IHC staining for downregulated TXNIP in FTE from three individual patients. F, Left, VCAM1 transcript expression in OVCAR3-, FT240-, and PBS-treated ciliated cells after 14 days. Right, IHC staining for upregulated VCAM1 in FTE from three individual patients. In all boxplots, each point represents normalized transcript abundance measured in a single segment. Scale bar, 20 μm; arrows indicate epithelium.

Article Snippet: Primary antibodies against CCL2 (Novus, cat. #NBP1-07035SS, RRID: AB_1625611), VCAM1 (Thermo Fisher Scientific, cat. #MA5-31965, RRID: AB_2809259), FLNA (Proteintech, cat. #67133-1-Ig, RRID: AB_2882432), TPI1 (Proteintech, cat. #10713-1-AP, RRID: AB_2207716), and TXNIP (Thermo Fisher Scientific, cat. #40-3700, RRID: AB_2533462) were incubated overnight at 4°C, followed by detection using a horseradish peroxidase–linked secondary antibody and DAB substrate (the full procedure is provided in the Supplementary Methods).

Techniques: Biomarker Discovery, Expressing, Immunohistochemistry